Protective Effects of Insulin and Incretins in AD/PD
Tuesday, March 9, 2021
13:30 – 18:40
No need to pre-register – participation is included in your Virtual Conference registration fees. To register for AD/PD™ 2021, please click here.
*Please note that the lectures in this session will be available for view on-demand
Session Chair: Christian Hölscher
Time |
Name |
Country |
Lecture Title |
---|---|---|---|
13:30-13:40 | Christian Hölscher | China | Welcome and Introduction |
13:40-14:00 | Suzanne Craft | USA | Intranasal insulin as a therapy for Alzheimer’s disease |
14:00-14:20 | Tom Foltynie | UK | Clinical trial of Bydureon (exenatide) in PD patients |
14:20-14:40 | Paul Edison | UK | Clinical trial of liraglutide in AD patients |
14:40-15:00 | Michele Tagliati | USA | Clinical trial of liraglutide in PD patients |
15:00-15:20 | Christian Hölscher (Moderator), Suzanne Craft, Tom Foltynie, Paul Edison and Michele Tagliati | LIVE Discussion | |
15:20-15:40 | Wassilios Meissner | France | Impaired brain insulin signaling in synucleinopathies: a translational study |
15:40-16:00 | Dimitrios Kapogiannis | USA | Insulin signaling biomarkers in blood exosomes of AD and PD patients |
16:00-16:20 | Konrad Talbot | USA | Direct demonstration of brain insulin resistance in Alzheimer’s and Parkinson’s disease dementia and its alleviation with incretin receptor agonists |
16:20-16:40 | William Banks | USA | Permeability of the blood-brain barrier to insulin and incretins |
16:40-17:00 | Nigel Greig (Moderator) Wassilios Meissner, Dimitrios Kapogiannis, Konrad Talbot and William Banks | LIVE Discussion | |
17:00-17:20 | Nigel Greig | USA |
GLUCAGON-LIKE PEPTIDE-1(GLP-1) RECEPTOR AGONISTS AS A TREATMENT STRATEGY FOR NEURODEGENERATIVE DISORDERS; FOCUSING ON PARKINSON’S DISEASE AND TRAUMATIC BRAIN INJURY |
17:20-17:40 | Ana Isabel Duarte | Portugal | The neuroprotective effects of insulin/IGF-1/GLP-1 signaling recovery in type 2 diabetes and neurodegenerative diseases |
17:40-18:00 | Christian Hölscher | China | Novel dual GLP-1/GIP receptor agonists and are superior to single receptor agonists in animal models of Alzheimer and Parkinson’s disease |
18:00-18:20 | Paul Edison (Moderator), Nigel Greig, Ana Isabel Duarte and Christian Hölscher | LIVE Discussion |